INSIGHTS ON SOLID DOSE MANUFACTURING

• Navigating OSD Formulation Development And Leveraging CDMO Partnership

  Collaborating with an experienced CDMO can provide the expertise and facilities needed to navigate oral solid dose formulation complexities and ensure compliance with regulatory frameworks.

• Integration From Formulation Development To Manufacturing, Packaging

  Adare Pharma Solutions' Pessano, Italy facility offers 220,000 sq. ft. of end-to-end services, including R&D, formulation development, clinical and commercial manufacturing, packaging, and advanced analytical capabilities.

• Rheological Properties Of Pharmaceutical Excipients: Lactose Monohydrate And Carboxymethyl Cellulose

  Explore lactose monohydrate and CMC rheology, highlighting their flow, cohesion, and compressibility properties to optimize pharmaceutical formulations under varying stress and temperature conditions.

• M6 Tablet Metal Detector For Pharmaceutical And Nutraceutical Production

  Ensure the safety and quality of your tablets and capsules with a metal detector designed for stability and high sensitivity in pharmaceutical and nutraceutical production.

• Taste-Masked Dosage Forms For Pediatric Oral Delivery: An Industrial Perspective

  7/18/2024

  Leveraging strategies and technologies for pediatric patient compliance for taste masking and controlled release in pharmaceutical products, enables flexibility in dosage and format options.

• Improving API Solubility Using Hot Melt Extrusion Formulation

  2/27/2025

  Solubility of active pharmaceutical ingredients (APIs) is a challenge in drug development. Discover how hot melt extrusion with polyvinyl alcohol enhances API solubility and stability to offer improved drug delivery.

• Raise Your Standards With Downflow Booth Airflow Containment

  1/30/2026

  Ensure personnel safety during hazardous material handling by mastering airflow dynamics and containment screens. Learn to achieve low exposure levels through advanced HEPA filtration methods.

• The Future Of Oral Solid Dose Development And Innovation

  2/27/2025

  Tom Sellig, CEO of Adare, discusses the ongoing relevance of small molecules, oral solid dose development, trends like GLP-1, and innovations like 3D printing in pharmaceuticals.

• Closing The Duration Gap In FDA-Approved Long-Acting Contraceptives

  7/17/2024

  A gap exists between three months and three years in FDA-approved long-acting contraceptives (LACs). A microsphere formulation enables sustained release over a six to twelve-month period.